Literature Analysis of Tuberculosis Induced by Adalimumab

Abstract

Abstract: Objective To investigate the characteristics and patterns of tuberculosis induced by adalimumab, to find its risk factors and provide technical support for safe and rational use of drugs in clinic. Methods Literatures of tuberculosis induced by adalimumab published until July 2018 were retrieved from CNKI, Wanfang database, VIP Chinese full-text database and Pubmed. According to inclusion and exclusion criteria, the literatures were analyzed. Results A total of 39 papers, 39 cases were included. The proportion of tuberculosis occurring in men was almost the same as women. Patients aged over 40 years old had the highest percentage(79.49%), and the primary disease was rheumatoid arthritis (41.02%). The rate of tuberculosis screening before medication was 97.44%. The incidence of extrapulmonary tuberculosis was 53.85%. 94.87% patients suffered tuberculosis within 3 years after drug use. One patient (2.56%) died. Conclusion Attention of medical staff should be paid to the risk of tuberculosis induced by adalimumab, and the rational follow-up should be made to ensure the safe drug use in clinic.

Key words: adalimumab, tuberculosis, literature analysis

CLC Number:

R994.11

CAI Jun, WEI Jing, JI Liwei. Literature Analysis of Tuberculosis Induced by Adalimumab[J]. Chinese Journal of Pharmacovigilance, 2018, 15(11): 682-685.

References

[1] 周兰兰,丁玉. 不同类型TNF拮抗剂治疗强直性脊柱炎发生不良反应的临床分析[J]. 上海交通大学学报(医学版), 2013,33(12):1620-1624.
[2] 范晓蕾,刘中华,岳涛,等. 血清TNF-α、IL-1β、IL-6和IL-17表达水平在阿达木单抗治疗活动性类风湿关节炎中的疗效预测作用[J].中国医科大学学报, 2018,47(6):556-561.
[3] 商瑜,何碧溪,常虹,等. 自身免疫性药物阿达木单抗在中国的发展现状[J]. 北京师范大学学报(自然科学版), 2015,51(6):591-594.
[4] Eng G P, Bouchelouche P, Bartels E M, et al.Anti-drug antibodies, drug levels, interleukin-6 and soluble TNF receptors in rheumatoid arthritis patients during the first 6 months of treatment with adalimumab or infliximab:a descriptive cohort study[J]. PLoS One,2016,11(9):e0162316.
[5] 张挺,李永吉,朱小春. 肿瘤坏死因子拮抗剂在类风湿关节炎中的应用进展[J]. 实用医学杂志, 2012,28(4):523-525.
[6] 王黎霞,成诗明,陈明亭,等. 2010年全国第五次结核病流行病学抽样调查报告[J]. 中国防痨杂志, 2012,34(8):485-508.
[7] Fina-Aviles F, Medina-Peralta M, Mendez-Boo L, et al.The descriptive epidemiology of rheumatoid arthritis in Catalonia: a retrospective study using routinely collected data[J]. Clin Rheumatol, 2016, 35(3):751-757.
[8] 中国医学会风湿病学分会. 2018中国类风湿关节炎诊疗指南[J]. 中华内科杂志, 2018,57(4):242-251.
[9] Keane J, Gershon S, Wise R P, et al.Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α-Neutralizing Agent[J]. N Engl J Med, 2001,345(15):1098-1104.
[10] 肿瘤坏死因子拮抗剂应用中结核病预防与管理专家建议组. 肿瘤坏死因子拮抗剂应用中结核病预防与管理专家共识[J]. 中华风湿病学杂志, 2013,17(8):508-513.
[11] Wang L, Turner M O, Elwood R K, et a1. A meta-analysis of the ffect of Bacille Calmette Guerin vaccination on tuberculin skin est measurements[J]. Thorax, 2002,57(9):804-809.
[12] Ponce de León D, Acevedo-Vásquez E, Sánchez-Torres A, et a1. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis[J]. Ann Rheum Dis, 2005,64(9):1360-1361.
[13] Abubakar I, Stagg H R, Whitworth H, et al.How should I interpret an interferon gamma release assay result for tuberculosis infection?[J]. Thorax, 2013,68(3):298-301.
[14] Winthrop K L, Weinblatt M E, Daley C L.You can't always get what you want, but if you try sometimes (with two tests-TST and IGRA-for tuberculosis) you get what you need[J]. Ann Rheum Dis, 2012,71(11):1757-1760.
[15] Pinto L M, Grenier J, Schumacher S G, et al.Immunodiagnosis of Tuberculosis: State of the Art[J]. Med Princ Pract, 2012,21(1):4.
[16] 梁东风,张江林,黄烽. 肿瘤坏死因子-α拮抗剂引发结核二例分析并文献复习[J]. 中华风湿病学杂志, 2008,12(10):700-704.
[17] Ketata W, Rekik W K, Ayadi H, et al.Extrapulmonary tuberculosis[J]. Rev Pneumol Clin, 2015,71(2-3):83-92.
[18] 刘江,代倩,钟慕晓,等. 潜伏性结核感染在英夫利西治疗前的筛查[J]. 实用医学杂志, 2017,33(2):298-300.
[19] 李名石,任瑜,杨悦. 美国药品说明书管理研究[J]. 中国药物警戒, 2014, 11(12):739-742.
[20] Sen S, Peltz C, Jordan, et al. Infliximab-induced nonspecific interstitial pneumonia[J]. Am J Med Sci, 2012,344(1):75-78.